ArticleSAGE open medicine2026
Prevalence of asthma and the premature mortality in Eastern sub-Saharan Africa, from 1990 to 2023.
Article in SAGE open medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is a paucity of information that characterized the burden of asthma in the Eastern Sub-Saharan African (ESSA) region. Therefore, this study estimated the prevalence of asthma and its premature mortality in the region from 1990 to 2023. Methods: Data on the prevalence of asthma and the years of life lost (YLL) were extracted from the Global Burden of Diseases 2023 database for the ESSA region. Asthma prevalence was estimated using disease modelling with a Bayesian meta-regression tool (DisMod-MR 2.1), whereas YLLs were derived using the Cause of Death Ensemble model (CODEm). The Comparative Risk Assessment Framework was applied to identify the risk factors for years of life lost. The spatiotemporal Gaussian process regression technique (ST-GPR) was used to smooth the trend. Age-standardized rates as well as the percentage change between 1990 and 2023 were estimated. Results: There were an estimated 20,716,738 prevalent cases (95% UI: 16,523,031-26,057,565) of asthma in the ESSA region in 2023, with an age-standardized rate of 4,324 cases per 100,000 population (95% UI: 3,555-5,261). There were an estimated 918,517 years of life lost (95% UI: 582,476-1,379,986) in the region and 297 age-standardized years of life lost per 100,000 population (95% UI: 221-487). No inter-country variations were estimated throughout the region. However, the YLLs rate increased with age. Occupational asthmagens, high body-mass index, sexual violence against children, and tobacco use were the leading risk factors for asthma-related premature mortalities in the region, with variable impacts by countries. Conclusion: There were high and persistent rates of morbidity and premature mortality from asthma in the ESSA region from 1990 and 2023. Targeted strategies are urgently needed to mitigate asthma risk factors and improve disease management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.